邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

粪菌移植治疗炎症性肠病的争议

张发明,  李玥

downloadPDF
文章导航 > 协和医学杂志  > 2019 >  10(3): 211-215
张发明, 李玥. 粪菌移植治疗炎症性肠病的争议[J]. 协和医学杂志, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005
引用本文: 张发明, 李玥. 粪菌移植治疗炎症性肠病的争议[J]. 协和医学杂志, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005
shu
Fa-ming ZHANG, Yue LI. Controversy of Fecal Microbiota Transplantation in Treating Patients with Inflammatory Bowel Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005
Citation: Fa-ming ZHANG, Yue LI. Controversy of Fecal Microbiota Transplantation in Treating Patients with Inflammatory Bowel Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 211-215. doi: 10.3969/j.issn.1674-9081.2019.03.005
shu

粪菌移植治疗炎症性肠病的争议

doi: 10.3969/j.issn.1674-9081.2019.03.005
  • 1.

    南京医科大学第二附属医院消化医学中心, 南京 210011

  • 2.

    南京医科大学附属逸夫医院微生态治疗科, 南京 211166

  • 3.

    中国医学科学院 北京协和医学院 北京协和医院消化内科, 北京 100730

基金项目: 

中国医学科学院医学与健康科技创新工程协同创新团队"人体微生物组平台建设与应用研究" 2017-I2M-3-017

江苏省重大研发计划 BE2018751

详细信息
    通讯作者:

    李玥 电话:010-69155751, E-mail:liyue@pumch.cn

  • 中图分类号: R459.9

Controversy of Fecal Microbiota Transplantation in Treating Patients with Inflammatory Bowel Disease

  • 1.

    Medical Center for Digestive Diseases, the Second Affiliated Hospital, Nanjing Medical University, Nanjing 210011, China

  • 2.

    Department of Microbiotherapy, the Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, China

  • 3.

    Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
    Corresponding author: LI Yue Tel:86-10-69155751, E-mail: liyue@pumch.cn

    摘要
  • 摘要: 已有报道表明粪菌移植治疗炎症性肠病前景可观, 且针对溃疡性结肠炎的临床随机对照研究支持粪菌移植的有效性。但涉及粪菌制备的方法学、移植途径、供体筛选、患者选择以及诱发病情活动的潜在风险等方面尚存诸多未知, 因此, 粪菌移植目前仅适合在临床试验等特定条件下用于炎症性肠病治疗。
    Abstract: Fecal microbiota transplantation (FMT) is reported to be a promising therapy for patients with inflammatory bowel disease(IBD). Randomized controlled trials have reported the effectiveness of FMT in the treatment of ulcerative colitis. However, many associated unknowns still remain, such as the preparation, the transplantation route, donor and recipient selection, and potential adverse events including the risk of IBD flare post-FMT. Therefore, FMT should only be administered in patients with IBD in a circumstanced setting, such as clinical trials.
    利益冲突  无
    • HTML全文

  • 图  1  基于智能粪菌分离系统的高级别净化实验室，仅用于从健康供体粪便中分离纯化菌群

    下载: 全尺寸图片 幻灯片
    • 参考文献(19)
  • [1] Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis:a randomised placebo-controlled trial[J]. Lancet, 2017, 389:1218-1228. doi:  10.1016/S0140-6736(17)30182-4
    [2] Costello SP, Hughes PA, Waters O, et al. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis:A Randomized Clinical Trial[J]. JAMA, 2019, 321:156-164. doi:  10.1001/jama.2018.20046
    [3] Ding X, Li Q, Li P, et al. Efficacy, safety and long-term follow up of step-up fecal microbiota transplantation strategy in moderate to severe ulcerative colitis[J]. Drug Saf, 2019.doi: 10.1007/s40264-019-00809-2.[Epub ahead of print].
    [4] Wang H, Cui B, Li Q, et al. The safety of fecal microbiota transplantation for Crohn's disease:Findings from long-term study[J]. Adv Ther, 2018, 35:1935-1944. doi:  10.1007/s12325-018-0800-3
    [5] Qazi T, Amaratunga T, Barnes EL, et al. The risk of inflammatory bowel disease flares after fecal microbiota transplantation:systematic review and meta-analysis[J]. Gut Microbes, 2017, 8:574-588. doi:  10.1080/19490976.2017.1353848
    [6] Kump P, Wurm P, Grochenig HP, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment[J]. Pharmacol Ther, 2018, 47, 67-77. https://pubmed.ncbi.nlm.nih.gov/29052237/
    [7] Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial[J].Gastroenterology, 2015, 149:102-109. doi:  10.1053/j.gastro.2015.04.001
    [8] Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis[J]. Gastroenterology, 2015, 149:110-118. doi:  10.1053/j.gastro.2015.03.045
    [9] Fuentes S, Rossen NG, van der Spek MJ, et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation[J]. ISME J, 2017, 11:1877-1889. doi:  10.1038/ismej.2017.44
    [10] Zhang F, Cui B, He X, et al. FMT-standardization Study Group. Microbiota transplantation:concept, methodology and strategy for its modernization[J]. Protein Cell, 2018, 9:462-473. doi:  10.1007/s13238-018-0541-8
    [11] Wilson BC, Vatanen T, Cutfield WS, et al. The Super-Donor Phenomenon in Fecal Microbiota Transplantation[J]. Front Cell Infect Microbiol, 2019, 9:2. doi:  10.3389/fcimb.2019.00002
    [12] Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective:clinical efficacy and bacterial viability data[J]. Aliment Pharmacol Ther, 2015, 42:1011-1018. doi:  10.1111/apt.13366
    [13] Staley C, Hamilton MJ, Vaughn BP, et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study[J]. Am J Gastroenterol, 2017, 112:940-947. doi:  10.1038/ajg.2017.6
    [14] Kao D, Roach B, Silva M, et al. Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection:a randomized clinical trial[J]. JAMA, 2017, 318:1985-1993. doi:  10.1001/jama.2017.17077
    [15] Uygun A, Ozturk K, Demirci H, et al. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis[J]. Medicine (Baltimore), 2017, 96:e6479. doi:  10.1097/MD.0000000000006479
    [16] Sood A, Mahajan R, Juyal G, et al. Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis:a real world intention-to-treat analysis[J]. Intest Res, 2019, 17:78-86. doi:  10.5217/ir.2018.00089
    [17] Li P, Zhang T, Xiao Y, et al. Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease[J]. Appl Microbiol Biotechnol, 2019, 103:349-360. doi:  10.1007/s00253-018-9447-x
    [18] Singh S, Feuerstein JD, Binion DG, et al. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis[J]. Gastroenterology, 2019, 156:769-808. doi:  10.1053/j.gastro.2018.12.008
    [19] Imdad A, Nicholson MR, Tanner-Smith EE, et al. Fecal transplantation for treatment of inflammatory bowel disease[J]. Cochrane Database Syst Rev, 2018, 11:CD012774. https://pubmed.ncbi.nlm.nih.gov/30480772/
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
图(1)
计量
  • 文章访问数:  313
  • HTML全文浏览量:  92
  • PDF下载量:  30
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-13
  • 刊出日期:  2020-09-18

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！